BioTuesdays

Tag - Ben Haynor

EyeGate Pharmaceuticals

AGP cuts EyeGate Pharma PT to $10.25 from $16.75

Alliance Global Partners reduced its price target for EyeGate Pharmaceuticals (NASDAQ:EYEG) to $10.25 from $16.75, citing a possible plan to sell additional common shares in the first half of this year in order to...

Sensus Healthcare Logo

AGP ups Sensus Healthcare PT to $7.50 from $2.95

Alliance Global Partners raised its price target for Sensus Healthcare (NASDAQ:SRTS) to $7.50 from $2.95, citing fourth quarter results that were well ahead of consensus estimates. The stock closed at $4.94 on March 1...

Reshape-Lifesciences-Logo

AGP starts ReShape Lifesciences at buy; PT $12

Alliance Global Partners initiated coverage of ReShape Lifesciences (OTCQB:RSLS) with a “buy” rating and price target of $12. The stock was quoted at $7.54 in afternoon trading on Feb. 18. ReShape is a rare pure-play in...

AGP starts Viveve Medical at buy; PT $10.75

Alliance Global Partners launched coverage of Viveve Medical (NASDAQ:VIVE) with a “buy” rating and price target of $10.75. The stock closed at $3.55 on Jan. 28. “After two disappointing, yet entirely explainable...

IMAC-Logo

AGP starts IMAC Holdings at buy; PT $2.75

Alliance Global Partners launched coverage of IMAC Holdings (NASDAQ:IMAC) with a “buy” rating and price target of $2.75. The stock closed at $1.05 on Nov. 16. IMAC offers regenerative medicine treatments including...

Heska-Corporation-Logo

AGP ups price target for Heska to $163.50 from $116.50

Alliance Global Partners raised its price target for Heska (NASDAQ:HSKA) to $163.50 from $116.50 after hosting an investor webcast with the company’s CEO. The stock closed at $116.41 on Nov. 3. Analyst Ben Haynor writes...

T2 Biosystems Logo

AGP ups T2 Biosystems PT to $1.65 from $1.10

Alliance Global Partners raised its price target for T2 Biosystems (NASDAQ:TTOO) to $1.65 from $1.10 after hosting an investor webcast with the company’s CEO and CFO. The stock closed at $1.34 on Oct. 30. “Our...

InspireMD

AGP starts InspireMD at buy; PT 70 cents

Alliance Global Partners initiated coverage of InspireMD (NYSE American:NSPR) with a “buy” rating and price target of 70 cents. The stock closed at 32 cent on Oct. 15. InspireMD has developed the CGuard EPS (Embolic...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.